Emory University School of Medicine
Assistant Chief of Hematology & Oncology
Atlanta VA Medical Center
Dr. Wayne B. Harris obtained his Medical Degree from Loma Linda University in 1988. He subsequently completed three years of specialty training in Internal Medicine at Emory University in Atlanta. After completing a service obligation to the National Health Scholarship Corps in Chattanooga, TN, he returned to Emory where he completed three additional years of subspecialty training in Hematology and Oncology. He joined the faculty of the Winship Cancer Institute in 1998 where he has focused on developing new treatments for kidney cancer and prostate cancer through clinical trials and translational research. Dr. Harris is a member of the Core Committee for Genitourinary Oncology of the Eastern Cooperative Oncology Group. Dr. Harris established the Oncology Research Clinic at the Atlanta VA Medical Center so that veterans can choose to participate in clinical research studies. At the VA, he serves as Emory’s principal investigator for such clinical trials as “S9346: Intermittent androgen deprivation in patients with stage D2 prostate cancer, phase III.” On Emory’s main campus, Dr. Harris has served as Emory’s principal investigator for clinical trials that focus on developing new treatments for kidney cancer in both early and advanced stages of the disease. Studies that have recently closed to accrual include “Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors” and E2805, “ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma.” Dr. Harris is also Emory’s principal investigator for current clinical trials for kidney cancer that are open to accrual including “E1808: Phase II randomized study of sunitinib malate with versus without gemcitabine hydrochloride in patients with advanced unresectable renal cell carcinoma with sarcomatoid features” and “E4805: A randomized phase II study to determine the effect of 2 different doses of AVE0005 (VEGF Trap) in patients with metastatic renal cell carcinoma.”
The most urgent projected clinical need over the next five years for patients with kidney cancer is the development of effective therapies for patients whose disease no longer responds to currently available therapies. In spite of the fact that more than a half a dozen new targeted therapies have been introduced since 2005, none of these new drugs has the ability to cure kidney cancer. A second related need is for biomarkers of early response or resistance to therapy as none exists at present. Dr. Harris views biomarkers of inflammation as potential candidates in this regard and has developed the Emory Dynamic Model for Kidney Cancer on this basis. He is using this model to develop several investigator-initiated studies for which he will serve as the principal investigator at the Winship Cancer Institute and with the Eastern Cooperative Oncology Group.
View publications on PubMed